Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival

By afschroeder • December 1, 2025

Crown J, Stroyakovskii D, Yardley DA, Huang CS, Fasching PA, Bardia A, Chia S, Im SA, Martin M, Xu B, Barrios CH, Untch M, Moroose R, Hurvitz SA, Hortobagyi GN, Slamon DJ, Visco F, Spera G, Zarate JP, Halligan D, Li Z, Loi S. Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival. ESMO Open. 2025 Nov;10(11):105858. doi: 10.1016/j.esmoop.2025.105858. Epub 2025 Oct 17. PMID: 41320342.

Tags: CDK4/6 inhibitor, early breast cancer, Hematology/Oncology, HR positive/HER2 negative, NATALEE, Publications, ribociclib

Molecular subtypes of hepatocellular carcinoma linked to liver cell lineages and clinical outcomes of combination immunotherapy

Wang Y, Guan Y, Abbas AR, Sano Y, Jain S, Lu S, Hamidi H, Koeppen H, Azuma Y, Kayukawa Y, Shinozuka J, Pochiraju A, Webster[...]

Tumor Extracellular Vesicle Digital Scoring Assays for Cancer Detection and Monitoring

Lee J, Zhao C, Yang J, Jonas SJ, Agopian V, You S, Posadas E, Yang JD, Zhu Y, Tseng HR. Tumor Extracellular Vesicle Digital Scoring[...]

GV1001, an hTERT-Derived Peptide, Prevents Cisplatin-Induced Nephrotoxicity by Preserving Mitochondrial Function

Chen W, Beheshtian C, Kim S, Kim R, Kim S, Park NH. GV1001, an hTERT-Derived Peptide, Prevents Cisplatin-Induced Nephrotoxicity by Preserving Mitochondrial Function. Cells. 2025[...]